115 related articles for article (PubMed ID: 35389589)
1. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
5. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
Patient Prefer Adherence; 2020; 14():517-527. PubMed ID: 32210539
[TBL] [Abstract][Full Text] [Related]
7. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
[TBL] [Abstract][Full Text] [Related]
8. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
[TBL] [Abstract][Full Text] [Related]
10. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Blauvelt A; Shi N; Burge R; Atiya B; Zhu B; Somani N; Ridenour T; Lew CR; Zimmerman NM; Murage MJ
Pharmacoecon Open; 2022 Nov; 6(6):871-880. PubMed ID: 36155891
[TBL] [Abstract][Full Text] [Related]
14. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
[TBL] [Abstract][Full Text] [Related]
16. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
18. Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.
Srulovici E; Garg V; Ghilai A; Feldman B; Hoshen M; Balicer RD; Skup M; Leventer-Roberts M
Adv Ther; 2018 May; 35(5):655-665. PubMed ID: 29748914
[TBL] [Abstract][Full Text] [Related]
19. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States.
Bergman M; Patel P; Chen N; Jing Y; Saffore CD
Rheumatol Ther; 2021 Mar; 8(1):109-118. PubMed ID: 33222113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]